Novartis reported $13B in Sales Revenues for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Abbvie ABBV:US USD 15.12B 309M
Amgen AMGN:US USD 6.84B 187M
Artemis Alpha ATS:LN GBP -25863000 16.53M
AstraZeneca AZN:LN USD 11.21B 225M
Biogen BIIB:US USD 2.54B 35.5M
Bristol Myers Squibb BMY:US USD 11.41B 188M
Eli Lilly And LLY:US USD 7.3B 360.2M
Gilead Sciences GILD:US USD 7.39B 347M
GlaxoSmithKline GSK:LN GBP 7.38B 453M
Johnson & Johnson JNJ:US USD 23.71B 85M
Merk MRK:US USD 13.83B 1.13B
Novartis NOVN:VX USD 13B 159M
Novartis NVS:US USD 13B 159M
Orion ORNBV:FH EUR 294.5M 197.3M
Pfizer PFE:US USD 24.29B 1.65B
Philips PHIA:NA EUR 5.42B 1.11B
Recordati REC:IM EUR 485.05M 11.94M
Regeneron Pharmaceuticals REGN:US USD 3.41B 478.2M